Skip to content
Screener

Arbutus Biopharma Corporation ABUS Unrealized Gains on Investments

Unrealized Gains on Investments at other companies

Gilead Sciences logo
Gilead SciencesGILD
$11M
Vir Biotechnology, Inc. logo
Vir Biotechnology, Inc.VIR
$192K-78.0%
Prime Medicine logo
Prime MedicinePRME
$0
Ligand Pharmaceuticals logo
Ligand PharmaceuticalsLGND
$63.48M+2,930%
BioCryst Pharmaceuticals logo
BioCryst PharmaceuticalsBCRX
$0-100%

Other financials

Income statement

See full
Revenue$1.0M-90.6%
Operating income-$6.0M-501%
Net income-$5.1M-304%
EPS (diluted)-$0.03-400%

Balance sheet

See full
Cash & equivalents$19.2M-48.8%
Total debt$514.0K-52.8%
Total equity$258.7M+212%
Total assets$274.0M+165%

Cash flow

See full
Operating cash flow-$6.0M+61.8%
CapEx--100%
Free cash flow-$4.7M+55.0%

Valuation

See full
Market cap$906.7M+41.2%
Enterprise value$888.04M+46.6%
P/E5.9×
P/S-36.7×

Profitability

See full
Operating margin82%+44.9pp
Net margin84.2%+46.6pp
FCF margin-281.5%-119pp

Returns & leverage

See full
Return on equity89.6%+65.3pp
Debt / equity0.0×
Current ratio81.4×+60.9×

Where this comes from

Reported directly by Arbutus Biopharma Corporation in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax.

The source filing: Arbutus Biopharma Corporation’s 10-Q, filed August 12, 2026.

Filed
Aug 12, 2026, 7:31 AM EDT
Fiscal quarter
Q3 FY2026
Calendar quarter
Q3 2026
Accession
0001447028-26-000045
As of June 30, 2026Amortized Cost / (in thousands)Gross Unrealized Gain(1) / (in thousands)Gross Unrealized Loss(1) / (in thousands)Fair Value / (in thousands)
Cash equivalents
Money market funds$6,914$6,914
US treasury bills$1,987$1,987
Total$8,901$8,901
Investments in marketable short-term securities
US treasury bills37,5121(30)37,483
US government bonds36,001(30)35,971
Total$73,513$1$(60)$73,454

ITEM 1. FINANCIAL STATEMENTS (UNAUDITED)

FAQ

What is Arbutus Biopharma Corporation's unrealized gains on investments?
Arbutus Biopharma Corporation (ABUS) reported unrealized gains on investments of $1K in Q2 2026.
How has Arbutus Biopharma Corporation's unrealized gains on investments changed year-over-year?
Arbutus Biopharma Corporation's unrealized gains on investments decreased by 88.9% year-over-year, from $9K to $1K.
What is the long-term trend for Arbutus Biopharma Corporation's unrealized gains on investments?
Over 2 years (2020 to 2025), Arbutus Biopharma Corporation's unrealized gains on investments has grown at a 140.8% compound annual growth rate (CAGR), from $15K to $87K.
What does unrealized gains on investments mean?
The total unrealized gains on investments, typically related to available-for-sale securities.

Ask your AI about Arbutus Biopharma Corporation's unrealized gains on investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude